Original Paper

Efficacy of Efalizumab in Psoriasis Patients Previously Treated with Tumour Necrosis Factor Blockers
A. Costanzo, M. Talamonti, E. Botti, G. Spallone, M. Papoutsaki, S. Chimenti

Department of Dermatology, University of Rome ‘Tor Vergata’, Rome, Italy

Address of Corresponding Author

Dermatology 2009;219:48-53 (DOI: 10.1159/000213758)

  Key Words

• Efalizumab
• Psoriasis
• Infliximab
• Etanercept

  Abstract

Background: Biological therapy for moderate to severe psoriasis includes tumour necrosis factor (TNF) blockers (infliximab, etanercept and adalimumab) and T-cell-targeting agents (efalizumab, alefacept) that act in different steps of a common pathogenic pathway. Large amounts of data coming from clinical trials indicate each of these drugs as highly effective and safe. However, little is known about the efficacy of a second biological therapy after the failure of the first. Objective: To evaluate whether the response to efalizumab in psoriasis patients was influenced by previous treatment with other biological agents. Patients and Methods: We have retrospectively analyzed a group of 155 psoriasis patients treated with efalizumab during the last 5 years and determined its efficacy in patients previously treated with anti-TNF drugs comparing it with the efficacy and safety observed in patients previously treated with traditional systemic drugs instead. Results: Efalizumab was shown to be as efficacious and safe in patients previously treated with biological agents as in those previously treated with traditional systemic drugs. Although not statistically significant, we observed a higher rate of response to efalizumab in patients previously treated with anti-TNF-α. PASI 75 was achieved at week 24 in 76.2% of the patients previously treated with biological agents versus 54.4% in patients previously treated with traditional drugs (OR = 2.9). Conclusions: These data suggest that efalizumab can be successfully used in psoriasis patients when TNF blockers cannot efficiently control the disease due to lack or loss of response, or when they have to be interrupted for intolerance or adverse events.

Copyright © 2009 S. Karger AG, Basel

  Author Contacts

Antonio Costanzo, MD
Department of Dermatology, University of Rome ‘Tor Vergata’
Viale Oxford 81
IT–00133 Rome (Italy)
Tel. +39 06 2090 2741, Fax +39 06 2090 2742, E-Mail antonio.costanzo@uniroma2.it

  Article Information

A.C. and M.T. equally contributed to this work. A.C. acted as paid speaker for Merck Serono and Wyeth and is the recipient of research grants from Wyeth; M.P. acted as paid speaker for Shering-Plough and Abbot; S.C. acted as paid speaker and is consultant for Wyeth, Merck Serono, Shering-Plough and Abbot.

Received: December 16, 2008
Accepted: February 16, 2009
Published online: April 16, 2009
Number of Print Pages : 6
Number of Figures : 1, Number of Tables : 3, Number of References : 23